Aristea Snags $63M In Series B

San Diego-based immunology startup Aristea Therapeutics says it has raised $63M in a Series B financing round, which was led by Fidelity Management & Research Company, LLC, along with Novo Holdings A/S, plus Arena Pharmaceuticals and funds managed by Tekla Capital Management, LLC. Aristea is a spinout of AstraZeneca, and is focused on clinical development of novel immunotherapy drugs for the treatment of orphan diseases. The company recently completed a Phase 2a study on its lead candidate, which is aimed at treating palmoplantar pustulosis (PPP). James M. Mackay, Ph.D. is President and CEO of Aristea.